G. Sarsenbayeva

Safety and immunogenicity of trivalent inactivated influenza vaccine in adults 60 years of age and older: a phase II, a randomized, comparative trial in Kazakhstan

M. Stukova, M. Orynbayev, M. Kassenov, 2020, Human vaccines & immunotherapeutics.

Safety and immunogenicity of the novel seasonal preservative‐ and adjuvant‐free influenza vaccine: Blind, randomized, and placebo‐controlled trial

Zhanna Buzitskaya, M. Stukova, M. Kassenov, 2018, Journal of medical virology.

Efficacy and safety of an inactivated whole-virion vaccine against COVID-19, QazCovid-in®, in healthy adults: A multicentre, randomised, single-blind, placebo-controlled phase 3 clinical trial with a 6-month follow-up

M. Stukova, Y. Burashev, K. Sultankulova, 2022, eClinicalMedicine.

Safety and immunogenicity of a QazCovid-in® inactivated whole-virion vaccine against COVID-19 in healthy adults: A single-centre, randomised, single-blind, placebo-controlled phase 1 and an open-label phase 2 clinical trials with a 6 months follow-up in Kazakhstan

M. Sergeeva, M. Stukova, K. Sultankulova, 2021, EClinicalMedicine.

Preclinical Evaluation of TB/FLU-04L—An Intranasal Influenza Vector-Based Boost Vaccine against Tuberculosis

M. Stukova, M. Kassenov, K. Vasilyev, 2023, International journal of molecular sciences.

Immunogenicity and safety of a novel seasonal influenza preservative-free vaccine manufactured in Kazakhstan: Results of a randomized, comparative, phase II clinical trial in adults

M. Stukova, M. Kassenov, B. Khairullin, 2018, Human vaccines & immunotherapeutics.